MYGN Stock Recent News

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Myriad Genetics' (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.

Investors are optimistic about Myriad Genetics' (MYGN) strong solvency position and improvement in testing volume.

Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.

Myriad Genetics (MYGN) registers a strong testing volume improvement across all its businesses in the fourth quarter of 2023.

Myriad Genetics, Inc. (MYGN) Q4 2023 Earnings Call Transcript

The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Myriad Genetics (MYGN) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.12 per share a year ago.

Management will also participate in two upcoming healthcare conferences Management will also participate in two upcoming healthcare conferences

Myriad Genetics demonstrates strong year-over-year growth in testing volumes and revenue in various segments of genetic testing. The company shows good management of costs and adjusts its revenue guidance, reflecting confidence in continued growth. Myriad Genetics strategically acquires assets to strengthen its operational efficiencies and position in oncology precision medicine.